Materials and methods involving hybrid vascular endothelial...

Details Materials and methods involving hybrid vascular endothelial... Materials and methods involving hybrid vascular endothelial...

2011-03-08

2011-03-08

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C536S023400

Reexamination Certificate

active

07902149

ABSTRACT:
The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth factors.

REFERENCES:
patent: 5498600 (1996-03-01), Murray et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 5776755 (1998-07-01), Alitalo et al.
patent: 5785965 (1998-07-01), Pratt et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 5851521 (1998-12-01), Branellec et al.
patent: 5928939 (1999-07-01), Eriksson et al.
patent: 5932540 (1999-08-01), Hu et al.
patent: 5935820 (1999-08-01), Hu et al.
patent: 5955291 (1999-09-01), Alitalo et al.
patent: 6040157 (2000-03-01), Hu et al.
patent: 6107046 (2000-08-01), Alitalo et al.
patent: 6130071 (2000-10-01), Alitalo et al.
patent: 6221839 (2001-04-01), Alitalo et al.
patent: 6235713 (2001-05-01), Achen et al.
patent: 6245530 (2001-06-01), Alitalo et al.
patent: 6331301 (2001-12-01), Eriksson et al.
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6403088 (2002-06-01), Alitalo et al.
patent: 6451764 (2002-09-01), Lee et al.
patent: 6576608 (2003-06-01), Lee et al.
patent: 6608182 (2003-08-01), Lee et al.
patent: 6645933 (2003-11-01), Alitalo et al.
patent: 6689580 (2004-02-01), Achen et al.
patent: 6730658 (2004-05-01), Alitalo et al.
patent: 6965010 (2005-11-01), Alitalo et al.
patent: 7309604 (2007-12-01), Alitalo et al.
patent: 2002/0120123 (2002-08-01), Rosen et al.
patent: 2002/0123481 (2002-09-01), Oliviero
patent: 2002/0127222 (2002-09-01), Achen et al.
patent: 2002/0182683 (2002-12-01), Hu et al.
patent: 2003/0008357 (2003-01-01), Hu et al.
patent: 2003/0028007 (2003-02-01), Hu et al.
patent: 2003/0125537 (2003-07-01), Achen et al.
patent: 2003/0166523 (2003-09-01), Achen et al.
patent: 2003/0166547 (2003-09-01), Oliviero et al.
patent: 2003/0166873 (2003-09-01), Lee et al.
patent: 2003/0211101 (2003-11-01), Wise et al.
patent: 2003/0211988 (2003-11-01), Epstein
patent: 2005/0032697 (2005-02-01), Alitalo et al.
patent: 2007/0142282 (2007-06-01), Alitalo et al.
patent: 0935001 (1999-08-01), None
patent: WO-91/02058 (1991-02-01), None
patent: WO-96/26736 (1996-09-01), None
patent: WO-97/09427 (1997-03-01), None
patent: WO-97/44453 (1997-11-01), None
patent: WO-98/02543 (1998-01-01), None
patent: WO-98/07832 (1998-02-01), None
patent: WO-98/20027 (1998-05-01), None
patent: WO-98/33917 (1998-08-01), None
patent: WO-99/30157 (1999-06-01), None
patent: WO-00/21560 (2000-04-01), None
patent: WO-00/24412 (2000-05-01), None
patent: WO-00/25805 (2000-05-01), None
patent: WO-00/45835 (2000-08-01), None
Achen et al.,Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4),Proc. Natl. Acad. Sci. USA, 95: 548-53 (1998).
Ataliotis et al., Distribution and functions of platelet-derived growth factors and their receptors during embryogenesis,Int. Rev. Cytology, 172: 95-127 (1997).
Barleon et al., Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1,Blood, 87: 3336-43 (1996).
Bellomo et al., Mice lacking the vascular endothelial growth factor-B gene (VEGF-B) have smaller heats, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia,Circ Res.E29-E35 (2000).
Betscholtz et al., Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: Implications for autocrine receptor activation,Cell, 39: 447-57 (1984).
Birkenhager et al., Synthesis and physiological activity of heterodimers comprising difference splice forms of vascular endothelial growth factor and placenta growth factor,Biochemical J., 316: 703-7 (1996).
Breier et al., Expression of vascular endothelial growth factor during embryonic andiogenesis and endothelial cell differentiation.Dev., 114 :521-32 (1992).
Cao et al., Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR,J. Biol. Chem., 271: 3154-62 (1996).
Chang et al., Evolution of a cytokine using DNA family shuffling,Nature Biotechnol., 17: 793-7 (1999).
Claesson-Welsh et al., cDNA cloning and expression of the human platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor,Proc. Natl. Acad. Sci. USA, 86: 4917-21 (1989).
Claesson-Welsh et al., cDNA cloning and expression of a human platelet-derived growth factor (PDGF) receptor specific for B-chain-containing PDGF molecules,Mol. Cell. Biol., 8: 3476-86 (1988).
Collins et al., Cultured human endothelial cells express platelet-derived growth factor B chain: cDNA cloning and structural analysis,Nature, 316: 748-50 (1985).
Cowling et al., Erythropoietin and myeloid colony stimulating factors,TIBTECH, 10:349-57 (1992).
DeVries et al., the fms-like tyrosine kinase, a receptor for vascular endothelial growth factor,Science, 255: 989-91 (1992).
Dumont et al., Cardiovascular failure in mouse embryos deficient in VEGF receptor-3,Science, 282:946-949 (1998).
EMBL database Account No. AF091434.
Fairbrother et al., Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site,Biochemistry, 37:17754-64 (1998).
Ferrara, Molecular and biological properties of vascular endothelial growth factor,J. Mol. Med., 77:527-43 (1999).
Ferrara et al., Clinical applications of angiogenic growth factors and their inhibitors,Nature Med., 5:1359-64 (1999).
Ferrell et al., Hereditary lymphedema: evidence for linkage and genetic heterogeneity,Hum. Mol. Genetics, 7: 2073-78 (1998).
Folkman et al., Long-term culture of capillary endothelial cells,Proc. Natl. Acad. Sci. USA, 76: 5217-21 (1979).
Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease,Nature Med., 1:27-31 (1995).
Friesel et al., Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction,FASEB J., 9: 919-25 (1995).
Fuh et al., Requirements for binding and signaling of the kinase domain receptor for vascualr endothelial growth factor,J. Biol. Chem., 273: 11197-204 (1998).
Gnatenko et al., Characterization of recombinant adeno-associated virus-2 as a vehicle for gene delivery and expression into vascular cells,J. Investig. Med., 45: 87-98 (1997).
Harayama et al., Artificial evolution by DNA shuffling,TIBTECH, 16: 76-82 (1998).
Hauser et al., A heparin-binding form of placenta growth factor (P1GF-2) is expressed in human umbilical vein endothelial cells and in placenta,Growth Factors, 9: 259-68 (1993).
Hein, Unified approach to alignment and phylogenies,Methods Enzymol., 183: 626-45 (1990).
Heldin et al., Structure of platelet-derived growth factor: implications for functional properties,Growth Factors, 8: 245-52 (1993).
Heldin et al., Signal transduction via platelet-derived growth factor receptors,Biochimica et Biophysica Acta, 1378: F79-113 (1998.).
Henikoff et al., Amino acid substitution matrices from protein blocks,Proc. Natl. Acad. Sci. USA, 89: 10915-9 (1992).
Isner et al., Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease,Circulation, 91: 2687-92 (1995).
Isner et al., Arterial gene therapy for restenosis,Human Gene Therapy, 7: 989-1011 (1996).
Jeltsch et al., Hyperplasia of lymphatic vessels in VEGF-C transgenic mice,Science, 276: 1423-5 (1997).
Joukov et al., Proteolytic processing regulates receptor specificity and activity of VEGF-C,The EMBO Journal, 16: 3898-911 (1997).
Joukov et al., Vascular endothelial growth factors VEGF-B and VEGF-C,J. Cell Physiol., 173: 211-5 (1997).
Joukov et al., Anovel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases,EMBO J., 15: 290-8 (1996).
Kaipainen et al., Expression of the fms-like

Affiliated with

Also associated with

Rating

Materials and methods involving hybrid vascular endothelial... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Materials and methods involving hybrid vascular endothelial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods involving hybrid vascular endothelial... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2726114